Drugmaker launches major safety watch for schizophrenia shot
NCT ID NCT01088386
Summary
This program aims to make a long-acting injectable medication for schizophrenia safer by closely monitoring patients for a rare but serious side effect. It enrolls all patients who receive the medication, Zyprexa Relprevv, to track their health and ensure they are observed in a certified healthcare facility after each injection. The goal is to better understand and reduce the risks associated with the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
United BioSource Corporation
Blue Bell, Pennsylvania, 19422, United States
Conditions
Explore the condition pages connected to this study.